Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 9/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.34 |
| ▸ | HRH2 | P25021 | 2/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15228417 | 1.00 | HRH1 (0.34) | HRH1HRH3HRH4HRH2STAT3 | |
| Hydrochloric Acid SCHEMBL28319672 | 0.98 | HRH1 (0.33) | HRH1HRH3HRH4HRH2STAT3 | |
| SCHEMBL31652590 | 0.98 | MAOA (0.33) | HRH1HRH3HRH4HRH2STAT3 | |
| SCHEMBL10626678 | 0.93 | GSK3A (0.37) | HRH1HRH3HRH4HRH2STAT3 | |
| SCHEMBL1887392 | 0.92 | HRH4 (0.31) | HRH3HRH4 | |
| SCHEMBL10428730 | 0.90 | STAT3 (0.39) | STAT3 | |
| SCHEMBL548131 | 0.90 | STAT3 (0.39) | STAT3 | |
| SCHEMBL10428620 | 0.90 | STAT3 (0.39) | STAT3 | |
| SCHEMBL6910095 | 0.90 | STAT3 (0.39) | STAT3 | |
| SCHEMBL549041 | 0.90 | STAT3 (0.39) | STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9763577-B2 | Imaging agent for detection of diseased cells | LUMICELL, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20140301950-A1 | IMAGING AGENT FOR DETECTION OF DISEASED CELLS | LUMICELL, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2014152389-A1 | IMAGING AGENT FOR DETECTION OF DISEASED CELLS | LUMICELL, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ENDACEA, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | ENDACEA, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1636230-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110379-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| EP-0306168-A1 | Preparation of radiolabeled conjugates | IMMUNOMEDICS, INC. (US) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140301950-A1 | IMAGING AGENT FOR DETECTION OF DISEASED CELLS | VHL, CD47, MKI67 | HRH1 3778/4885HRH3 2885/4885HRH4 3895/4885 |
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | HRH3, HRH1, HRH2 | HRH1 2/4885HRH3 1/4885HRH4 6/4885 |
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ADORA1, ADORA3, ADORA2A | HRH1 6/4885HRH3 5/4885HRH4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.